Mizuho Downgrades Waters to Neutral on Pharma Concerns | GenomeWeb

NEW YORK (GenomeWeb News) – Investment firm Mizuho today downgraded Waters, citing "choppiness around the pharmaceutical market" that may cause the company's stock to "languish."

Analyst Peter Lawson downgraded Waters to Neutral from a Buy rating but maintained the $110 price target on the company's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.